MRNA — Moderna, Inc. (Stock)

Price: $182.11 · 1 day: -0.25% · 5 days: +25.06% · 1 month: +31.12% · YTD: +517.53%
As of 2026-09-23 20:00 UTC.

52-week range: $22.28 – $192.31 (currently at 94% of the range).

The read

MRNA is in an uptrend, momentum firm. $182.56 is the level overhead; $175 the first support below.

6 of 6 technical checks lean bullish.

• Price vs 50-day: above
• Price vs 200-day: above
• 50d vs 200d avg: above
• MACD: bullish
• RSI momentum: 70
• 5-day tape: +25.1%

Key levels

Indicators

Next earnings: 2026-11-05.

Latest MRNA news

• Stocks had a great day on the surface. But something alarming occurred not seen since 1999 — Despite the S&P 500 gaining 1.5% and the Nasdaq Composite surging 2% to record highs on Monday, market breadth deteriorated significantly with 30 stocks hitting new 52-week lows compared to only 7 reaching new highs. Thi (CNBC, 2026-09-21)
• AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033 — The global AI in drug discovery market is projected to reach $13.8 billion by 2033, according to Grand View Research, reflecting rapid expansion as artificial intelligence becomes more central to pharmaceutical developme (The Wall Street Journal, 2026-09-21)
• Money-losing Nscale's $35 billion IPO includes a $3 billion deal with Nvdia and 'going concern' worries | Fortune — Nscale, an AI cloud company, has filed for a $35 billion IPO despite reporting a $1 billion net loss on $140.6 million in revenue for the first half of 2026, with cost of revenue exceeding revenue and resulting in a gros (Fortune, 2026-09-21)
• HDT Bio Receives ARPA-H GIVE Award to Lead Development of Automated, Point-of-Care Manufacturing for Personalized RNA Medicines — HDT Bio announced receipt of an ARPA-H GIVE program award providing $5.2 million in Phase 1 funding with total potential value up to $39.5 million to develop an automated, point-of-care manufacturing platform for persona (PR Newswire, 2026-09-15)
• A Breakthrough Cancer Vaccine Fueled a Biotech Rally. Can It Last? - WSJ's Take On the Week - WSJ Podcasts — A breakthrough cancer vaccine development triggered a significant rally in biotech stocks, raising questions about the sustainability of the sector's momentum. The vaccine announcement represents a major clinical milesto (The Wall Street Journal, 2026-09-14)
• AI Drug Discovery Market Projected to Reach $13.8 Billion by 2033 — # Summary The global AI in drug discovery market is projected to grow from $2.9 billion in 2026 to $13.8 billion by 2033, representing a compound annual growth rate of approximately 24.8%, according to Grand View Resear (PR Newswire, 2026-09-14)
• Stocks making the biggest moves premarket: Snowflake, Moderna, Broadcom & more — Multiple publicly traded companies experienced significant premarket movements following earnings reports and guidance updates. Snowflake led gainers with a 24% surge after beating Q2 expectations with adjusted EPS of $0 (CNBC, 2026-09-03)
• Moderna, Inc. — Form 8-K: 1.01 Entry into a Material Agreement; 2.03 Creation of a Material Financial Obligation; 3.02 Unregistered Sale of Equity Securities; 8.01 Other Events; 9.01 Financial Statements and Exhibits — Moderna, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission on September 1, 2026. The filing disclosed several items, including entry into a material agreement, the creation of a material financial ob (SEC EDGAR, 2026-09-01)

Explore more

Interactive MRNA chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs